| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7772243 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
Aug, 2028
(4 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8623883 | PFIZER | 4-phenylamino-quinazolin-6-yl-amides |
May, 2025
(1 year, 5 days from now) | |
| US10596162 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(1 year, 9 months from now) | |
| US10603314 | PFIZER | Method for treating gefitinib resistant cancer |
Feb, 2026
(1 year, 9 months from now) | |
Vizimpro is owned by Pfizer.
Vizimpro contains Dacomitinib.
Vizimpro has a total of 4 drug patents out of which 0 drug patents have expired.
Vizimpro was authorised for market use on 27 September, 2018.
Vizimpro is available in tablet;oral dosage forms.
Vizimpro can be used as administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib or erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution with t790m mutation, administering daily a unit dosage of an irreversible egfr inhibitor covalently binding as claimed for 1st line treatment of gefitinib of erlotinib resistant metastatic nsclc with egfr exon 19 deletion or exon 21 l858r substitution, first-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test.
Drug patent challenges can be filed against Vizimpro from 27 September, 2022.
The generics of Vizimpro are possible to be released after 26 August, 2028.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity(ODE-206) | Sep 27, 2025 |
| Orphan Drug Exclusivity(ODE-213) | Sep 27, 2025 |
| New Chemical Entity Exclusivity(NCE) | Sep 27, 2023 |
Drugs and Companies using DACOMITINIB ingredient
NCE-1 date: 27 September, 2022
Market Authorisation Date: 27 September, 2018
Treatment: First-line treatment of metastatic non small-cell lung cancer (nsclc) with egfr exon 19 deletions or exon 21 (l858r) substitution mutations as detected by an fda-approved test; Administering daily a u...
Dosage: TABLET;ORAL
VIZIMPRO family patents
